Hans-Peter Kiem, M.D., Ph.D.

faculty member

Hans-Peter Kiem, M.D., Ph.D.

Director, Stem Cell and Gene Therapy Program
Clinical Research Division, Fred Hutch

Associate Head of Transplantation Biology
Clinical Research Division, Fred Hutch

Vaccine and Infectious Disease Division, Fred Hutch

Clinical Research Division, Fred Hutch

Stephanus Family Endowed Chair for Cell and Gene Therapy
Fred Hutch

Fax: 206.667.6124
Mailstop: D1-100

Dr. Hans-Peter Kiem is a world-renowned pioneer in stem-cell and gene therapy and in the development of new gene-editing technologies. His focus has been the development of improved treatment and curative approaches for patients with genetic and infectious diseases or cancer. For gene editing, his lab works on the design and selection of enzymes, known as nucleases, which function as molecular scissors capable of accurately disabling defective genes. By combining gene therapy’s ability to repair problem-causing genes and stem cells’ regenerative capabilities, he hopes to achieve cures of diseases as diverse as HIV, leukemia and brain cancer. With preclinical models of HIV, Dr. Kiem and his colleagues have demonstrated that they can modify a key viral entry gene and prevent it from working in transplanted blood stem cells. He also hopes to apply these technologies to cure genetic blood disorders such as Fanconi anemia and sickle cell disease.

Other Appointments & Affiliations

University of Washington School of Medicine

Associate Head, Heme Malignancy Program
University of Washington /Fred Hutch Cancer Consortium

Attending Physician, Medical Oncology
Seattle Cancer Care Alliance

José Carreras / E. Donnall Thomas Endowed Chair for Cancer Research 2009-2014
Fred Hutch


M.D., University of Ulm, Germany, 1987

Ph.D., Medicine, University of Ulm, 1988

Research Interests

Stem cell and transplantation biology, cell and gene therapy and the development and use of novel gene editing technologies.

Current Projects

Understand basic hematopoietic stem cell (HSC) and transplantation biology and clonal composition of hematopoiesis after transplantation, especially the clonality of gene-modified HSCs

Develop and evaluate novel virus-based gene therapy technology and nuclease technology including megaTals, zinc finger nucleases and CRISPR/Cas technology to edit hematopoietic cells with the goal to improve the treatment for genetic and infectious diseases and cancer.

Develop novel ways to derive HSCs from induced pluripotent stem cells (iPSCs) and to expand HSCs to facilitate gene therapy and stem cell transplantation

Develop clinical gene therapy protocols for genetic and acquired diseases, including cancer. Current target diseases include Fanconi anemia, severe combined immunodeficiency, hemoglobinopathies, glioblastoma, and HIV

Develop less toxic hematopoietic cell transplantation protocols especially for patients with nonmalignant diseases


"Stem cells can do everything. If we can correct defective stem cells, we can cure diseases."

—Dr. Hans-Peter Kiem

Find A Clinical Trial

For the Media

The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.

Email media@fredhutch.org or call 206.667.2210